Eupraxia Pharmaceuticals (EPRX) Stock Chart & Stock Price History $5.32 -0.13 (-2.31%) As of 12:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Eupraxia Pharmaceuticals Stock Price Performance The Eupraxia Pharmaceuticals (EPRX) stock chart highlights key performance trends across multiple timeframes. Over the last 12 months, the stock's price has increased 103.98%, with a year-to-date return of 67.95%. In the past month, the stock has decreased 4.76%, reflecting recent market activity. As of the latest close, Eupraxia Pharmaceuticals traded at $5.45 with a market cap of $195.98 million and volume of 6,637 shares. Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address 5 Day Performance+1.22%1 Month Performance-4.76%3 Month Performance+35.13%Year-To-Date Performance+67.95%1 Year Performance+103.98% EPRX Stock Chart for Thursday, August, 14, 2025 EPRX Chart by TradingView Eupraxia Pharmaceuticals Stock Price History Daily Weekly Monthly Yearly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 3 Year 5 Year Time Frame Start Date End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization08/13/2025$5.38$5.45+1.32%$5.58$5.416,637 shs$195.98 million08/12/2025$5.32$5.38+1.11%$5.41$5.2118,142 shs$193.43 million08/11/2025$5.26$5.32+1.14%$5.42$5.2015,869 shs$191.31 million08/08/2025$5.36$5.26-1.88%$5.26$5.225,124 shs$189.15 million08/07/2025$5.42$5.36-1.09%$5.46$5.363,704 shs$192.78 million08/06/2025$5.36$5.42+1.12%$5.45$5.377,737 shs$194.90 million08/05/2025$5.37$5.36-0.09%$5.39$5.212,644 shs$192.75 million08/04/2025$5.30$5.37+1.15%$5.40$5.261,703 shs$192.93 million08/01/2025$5.40$5.30-1.78%$5.35$5.184,758 shs$190.73 million07/31/2025$5.29$5.40+2.08%$5.66$5.2016,029 shs$194.18 million Get the Latest News and Ratings for EPRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 07/30/2025$5.58$5.29-5.20%$5.56$5.2526,227 shs$190.23 million07/29/2025$5.64$5.58-0.99%$5.58$5.555,589 shs$200.64 million07/28/2025$5.49$5.64+2.66%$5.67$5.4724,864 shs$202.67 million07/25/2025$5.54$5.49-0.90%$5.60$5.3431,871 shs$197.42 million07/24/2025$5.14$5.54+7.70%$5.69$5.3026,534 shs$199.22 million07/23/2025$5.07$5.14+1.48%$5.14$5.012,239 shs$184.96 million07/22/2025$5.09$5.07-0.31%$5.13$4.884,743 shs$182.28 million07/21/2025$5.29$5.09-3.88%$5.26$5.106,869 shs$182.86 million07/18/2025$5.41$5.29-2.22%$5.38$5.264,195 shs$190.23 million07/17/2025$5.35$5.41+1.12%$5.47$5.303,484 shs$194.54 million07/16/2025$5.35$5.35+0.02%$5.60$5.3512,275 shs$192.37 million07/15/2025$5.59$5.35-4.31%$5.61$5.383,393 shs$192.35 million07/14/2025$5.44$5.59+2.78%$5.64$5.3122,873 shs$201.02 million Related Companies Nuvation Bio Stock Chart Immatics Stock Chart Sionna Therapeutics Stock Chart uniQure Stock Chart Mind Medicine (MindMed) Stock Chart Amylyx Pharmaceuticals Stock Chart Niagen Bioscience Stock Chart Stoke Therapeutics Stock Chart Valneva Stock Chart Tango Therapeutics Stock Chart Receive EPRX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Eupraxia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:EPRX) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBig Changes Coming in August — Is Your IRA Ready?Banks aren’t waiting for the headlines to catch up. They’ve already started moving their wealth out of pape...Reagan Gold Group | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eupraxia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eupraxia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access